Latest Breaking News On - Ikena oncology - Page 6 : comparemela.com

Osiris Therapeutics (OTCMKTS:OSIR) and Ikena Oncology (NASDAQ:IKNA) Head-To-Head Comparison

Osiris Therapeutics (OTCMKTS:OSIR – Get Free Report) and Ikena Oncology (NASDAQ:IKNA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. Profitability This table compares Osiris Therapeutics and […]

United statesOsiris therapeuticsIkena oncology incOsiris therapeutics incGet free reportIkena oncologyGiven ikena oncologyOsiris therapeutics dailyOtcmkts osirStock comparisonStock analysis

Ikena Oncology (NASDAQ:IKNA) Rating Reiterated by William Blair

William Blair restated their outperform rating on shares of Ikena Oncology (NASDAQ:IKNA – Free Report) in a report published on Thursday morning, RTT News reports. Several other analysts have also weighed in on IKNA. HC Wainwright dropped their price objective on shares of Ikena Oncology from $18.00 to $11.00 and set a buy rating for […]

United statesWilliam blairBlackrock incVanguard group incIkena oncology company profileJpmorgan chase coCharles schwab investment management incIkena oncology incIkena oncologyFree reportSchwab investment managementState street corpStreet corpGet free reportIkena oncology dailyNasdaq ikna

Ikena Oncology s (IKNA) Outperform Rating Reaffirmed at William Blair

William Blair reaffirmed their outperform rating on shares of Ikena Oncology (NASDAQ:IKNA – Free Report) in a report issued on Thursday, RTT News reports. Several other analysts have also recently issued reports on the stock. Wedbush initiated coverage on shares of Ikena Oncology in a research note on Thursday, September 21st. They set an outperform […]

United statesWilliam blairIkena oncology incIkena oncology company profileArtal groupCitadel advisorsBlackrock incIkena oncologyFree reportGet free reportIkena oncology dailyNasdaq iknaReiterated rating

Ikena Oncology, Inc (NASDAQ:IKNA) to Post Q2 2024 Earnings of ($0 44) Per Share, HC Wainwright Forecasts

Ikena Oncology, Inc. (NASDAQ:IKNA – Free Report) – Equities research analysts at HC Wainwright issued their Q2 2024 earnings per share estimates for shares of Ikena Oncology in a note issued to investors on Thursday, November 9th. HC Wainwright analyst A. Maldonado expects that the company will post earnings of ($0.44) per share for the […]

United statesDimensional fund advisorsCharles schwab investment management incBlackrock incBarclays plcIkena oncology company profileJpmorgan chase coIkena oncology incIkena oncologyFree reportOncology stock downSchwab investment managementFund advisorsGet free reportIkena oncology dailyNasdaq ikna

DelveInsight Business Research, LLP: Neurofibromatosis Type 2 Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - Novartis, AstraZeneca, GlaxoSmithKline, Ikena, SpringWorks, Vivace, Recursion

DelveInsight Business Research, LLP: Neurofibromatosis Type 2 Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - Novartis, AstraZeneca, GlaxoSmithKline, Ikena, SpringWorks, Vivace, Recursion
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesRheinland pfalzUnited kingdomPrnewswire delveinsightShruti thakurRecursion pharmaceuticals incShanghai fosun pharmaceutical development co ltdChia tai tianqing pharmaceutical group co ltdBetta pharmaceuticals co ltdNovartis pharmaceuticalsSpringworks therapeutics incRecursion pharmaceuticalsVivace therapeutics incMarket researchNeurofibromatosis typeVivace therapeutics